Universität zu Köln

Journal Article

Faivre, Sandrine J., Santoro, Armando ORCID: 0000-0003-1709-9492, Kelley, Robin Kate, Merle, Philippe, Gane, Ed, Douillard, Jean-Yves, Waldschmidt, Dirk, Mulcahy, Mary Frances, Costentin, Charlotte, Minguez, Beatriz ORCID: 0000-0002-7276-9666, Papappicco, Pasqua, Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Lahn, Michael M., Ameryckx, Sophie, Benhadji, Karim A., Raymond, Eric and Giannelli, Gianluigi (2014). A phase 2 study of a novel transforming growth factor-beta (TGF-beta 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 32 (3). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Javle, Milind, Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa ORCID: 0000-0002-5856-4082, Weiss, Karl Heinz, Waldschmidt, Dirk-Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony, Borad, Mitesh J., Yong, Wei Peng, Philip, Philip A., Bitzer, Michael, Tanasanvimon, Surbpong, Li, Ai, Pande, Amit, Soifer, Harris S., Shepherd, Stacie Peacock, Moran, Susan, Zhu, Andrew X., Bekaii-Saab, Tanios S. and Abou-Alfa, Ghassan K. (2021). Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol., 6 (10). S. 803 - 816. SAN DIEGO: ELSEVIER INC. ISSN 2468-1253

Javle, Milind M., Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Waldschmidt, Dirk Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony B., Yong, Wei-Peng, Philip, Philip Agop, Bitzer, Michael, Tanasanvimon, Suebpong, Pande, Amit, Shepherd, Stacie Peacock, Moran, Susan and Abou-Alfa, Ghassan K. (2021). Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Makawita, Shalini, Kelley, Robin Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Yong, Wei-Peng, Borbath, Ivan, El-Khoueiry, Anthony B., Philip, Philip Agop, Moran, Susan, Ye, Yining, Soifer, Harris S., Li, Gary, Berman, Craig and Javle, Milind M. (2020). Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions. J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755